文献速递肝病

随机临床研究:口服牛磺酸6克/天与安慰剂对门静脉高压的影响

Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension.
PubMed 文献 · Aliment Pharmacol Ther · 2017-11-03

这项前瞻性概念验证研究纳入肝静脉压力梯度(HVPG)≥12 mmHg的肝硬化伴静脉曲张患者,比较口服牛磺酸6 g/天与安慰剂4周对HVPG的影响。牛磺酸组平均HVPG从基线20 mmHg(±4)降至第28天18 mmHg(±4),安慰剂组从20 mmHg(±5)升至21 mmHg(±5)。牛磺酸可能降低肝硬化患者门静脉压力,且安全性良好。

要点

  • 牛磺酸组平均HVPG相对变化-12%(P=0.0093),安慰剂组+2%(P=0.4945)。
  • 牛磺酸组12例中7例(58%)HVPG应答>10%,安慰剂组无一例应答(P=0.0053)。
  • 治疗相关不良事件包括胃肠道不适和疲劳,通常轻微且两组相当。

核心结论

  • 牛磺酸安全,可能降低肝硬化患者的门静脉压力。
  • 需要更多关于牛磺酸补充作用机制和长期效果的研究。

研究设计与样本

  • 前瞻性概念验证研究,纳入HVPG≥12 mmHg的肝硬化伴静脉曲张患者,不允许合并使用非选择性β受体阻滞剂。
  • 患者随机接受4周口服牛磺酸(6 g/天)或安慰剂,随后评估HVPG应答。
  • 30例患者接受筛选,22例纳入疗效分析(牛磺酸组12例/安慰剂组10例;男性64%,平均年龄52±11岁,Child A级9%、B级64%、C级27%,腹水68%)。

主要发现

  • 牛磺酸组平均HVPG从基线20 mmHg(±4)降至第28天18 mmHg(±4),平均相对变化-12%(P=0.0093)。
  • 安慰剂组平均HVPG从基线20 mmHg(±5)升至第28天21 mmHg(±5),平均相对变化+2%(P=0.4945)。
  • 牛磺酸对全身血流动力学无显著影响。
  • 牛磺酸组12例中7例(58%)达到HVPG应答>10%,安慰剂组无一例达到(P=0.0053)。
  • 多变量线性模型中,牛磺酸组HVPG下降显著大于安慰剂组(绝对变化P=0.0091,相对变化P=0.0109)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要更多关于牛磺酸补充作用机制和长期效果的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The amino sulphonic acid taurine reduces oxidative endoplasmatic reticulum stress and inhibits hepatic stellate cell activation, which might lead to reduction of portal pressure in cirrhosis. AIM: To assess the haemodynamic effects of taurine supplementation in patients with cirrhosis and varices. METHODS: Patients with hepatic venous pressure gradient (HVPG) ≥12 mm Hg were included in this prospective proof of concept study. Concomitant nonselective beta-blockers therapy was not allowed. Patients received either 4 weeks of oral taurine (6 g/day), or placebo, prior to evaluation of HVPG response. RESULTS: Thirty patients were screened and 22 included in the efficacy analysis (12 taurine/10 placebo; 64% male, mean age: 52 ± 11 years, Child A: 9%, B:64%, C:27%, ascites:68%). In the taurine group, mean HVPG dropped from 20 mm Hg (±4) at baseline to 18 mm Hg (±4) on day 28 (mean relative change: -12%, P = .0093). In the placebo group, mean HVPG increased from 20 mm Hg (±5) at baseline to 21 mm Hg (±5) on day 28 (mean relative change:+2%, P = .4945). Taurine had no significant effects on systemic haemodynamics. Seven of 12 patients (58%) on taurine achieved a HVPG response >10%, compared to none in the placebo group (P = .0053). In a multivariate linear model, HVPG reduction was significantly larger in the taurine group compared to placebo group (P = .0091 and P = .0109 for absolute and relative change respectively). Treatment-related adverse events included gastrointestinal discomfort and fatigue, and were usually mild and comparable between treatment groups. CONCLUSION: Taurine is safe and may reduce portal pressure in cirrhotic patients. More studies on the underlying mechanisms of action and long-term effects of taurine supplementation are warranted.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Schwarzer R, Kivaranovic D, Mandorfer M, et al. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. Aliment Pharmacol Ther. 2017. PMID: 29105115. doi:10.1111/apt.14377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。